Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

1 treatments under study, led by Interferon Gamma1b

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Recruiting1
Terminated1
Completed1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06491615RecruitingPrimary

National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases

NCT00378742Completed

Repository for Inherited Eye Diseases

NCT02338973Phase 1/2TerminatedPrimary

Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)

Showing all 3 trials

Research Network

Common Treatments

  • Interferon Gamma1b1

Active Sponsors

  • National Eye Institute (NEI)3

Top Investigators

Related Conditions

  • Corneal Dystrophy1
  • Bluecone Monochromacy1
  • Aniridia1
  • Albinism1
  • Retinitis Pigmentosa1

Activity Timeline